Abstract: The invention provides a pharmaceutical agent delivery composition comprising: (i) a transport polymer comprising a linear or branched peptide having from about 10 to about 300 amino acid residues, having from about 5 to 100% histidine residues, and optionally having from 0 to about 95% non-histidine amino acid residues; (ii) at least one pharmaceutical agent; and optionally (iii) one or more intracellular delivery components in association with the transport polymer. The invention also provides methods for using such composition to deliver the pharmaceutical agent to the interior of cells.

Abstract: The invention provides a human calcium binding protein (hCBP) and polynucleotides which identify and encode hCBP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of hCBP.

Abstract: The invention features methods for the prevention or treatment of autoimmune disorders in humans. The methods include administering an autoantigen in combination with an oil-based carrier. Included are methods for the prevention and treatment of diabetes mellitus which include treating a patient with a diabetes type 1 autoantigen, e.g., human insulin B-chain or GAD65, and an oil-based carrier approved for human use. Also included are vaccines and kits for the treatment of diabetes mellitus.

Abstract: Compositions and methods for the therapy, diagnosis and monitoring of breast cancer are disclosed. Compositions may comprise one or more mammaglobin epitopes, or antibodies or T cells thereto, and may be used, for example, for the prevention and treatment of breast cancer. Diagnostic methods based on detecting the presence of mammaglobin epitopes, or antibodies or T cells thereto, in a sample are also provided. Also provided are methods for detecting RNA encoding mammaglobin in patient blood or fractions thereof. These methods may be used to detect and/or monitor the progression of breast cancer.

Abstract: A mammal with congestive heart failure is treated by administering to the mammal an effective amount of growth hormone Treatment results in increased left ventricular cystolic pressure, increased left ventricular maximum, increased cardiac output, and increased stroke volume index Treatment also results in reduced left ventricular end-diastolic pressure and reduced systemic vascular resistance. These measurements indicate improvement in cardiac function by increased ventricular contractility and decreased peripheral vascular resistance.

Abstract: The invention provides novel methods and compositions for modulating gluconeogenesis through modulation of PGC-1 activity or expression. Also provided are methods for identifying compounds that modulate gluconeogenesis through modulation of PGC-1 activity or expression, as well as methods for identifying compounds that modulate the interaction of PGC-1 with PGC-1 target molecules. Further provided are methods for treating disorders characterized by aberrant gluconcogenesis.

Abstract: Vascular endothelial cell growth factor II is purified from the culture media used to maintain mammalian glioma cells. The protein is a heterodimer, stimulates mitogenesis of mammalian vascular endothelial cells and is useful for the promotion of vascular development and repair. This unique growth factor is also useful in the promotion of tissue repair.

Abstract: This invention provides an isolated nucleic acid encoding an insect gustatory or odorant receptor. This invention provides a nucleic acid of at least 12 nucleotides capable of specifically hybridizing with a nucleic acid encoding an insect gustatory or odorant receptor. This invention also provides a purified, insect gustatory or odorant receptor. This invention provides an antibody capable of specifically binding to an insect gustatory or odorant receptor. This invention provides a method of identifying a compound capable of specifically binding to, activating, or inhibiting the activity of an insect gustatory or odorant receptor. This invention also provides methods of controlling insect populations.

Abstract: The present invention is directed to compositions comprising: (a) a first component selected from the group consisting of L-arginine, polypeptides thereof, acceptable salts thereof, pro-forms thereof, and mixtures thereof; and (b) a second component selected from the group consisting of sterols, stanols, esters thereof, polyol fatty acid polyesters, and mixtures thereof. The present invention is further directed to kits comprising these compositions as well as methods of using the compositions. The compositions, kits, and methods herein are useful for providing general health benefits to the consumer, particularly cardiovascular benefits, anti-menopausal benefits and/or treating sexual dysfunction (particularly, erectile dysfunction). Most particularly, the compositions, kits, and methods herein are useful for providing cardiovascular benefits, including lowering cholesterol in the consumer, treating, preventing, and/or inhibiting heart disease (e.g.

Abstract: The present invention relates to a pharmaceutical composition containing a mixture of stable folding variants of recombinant bone morphogenic proteins (rBMPs) and its use in therapy, especially in the treatment of orthopaedic and dental patients. Specifically, the present invention relates to a pharmaceutical composition containing a mixture of stable folding variants of at least two rBMPs or their monomers or mutants in a suitable carrier system.

Abstract: A method for reducing the incidence or delaying the onset of diabetes in diabetes-susceptible mammals (e.g., mice, rats, humans) is provided wherein the mammals are treated with a gonadotropin-releasing hormone (GnRH) antagonist. Additionally, the present invention provides a method of prolonging the honeymoon phase and decreasing the rate of islet cell infiltration by lymphocytes by administration of a GnRH antagonist. Preferably, the antagonist is administered repeatedly over time by subcutaneous injection. Preferred antagonists include Acetyl-&bgr;-[2-Naphthyl]-D-Ala-D-p-Chloro-Phe-&bgr;-[3-Pyridyl]-D-Ala-Ser-N&egr;-[Nicotinoyl]-Lys-N&egr;-[Nicotinoyl]-D-Lys-Leu-N&egr;-[Isopropyl]-Lys-Pro-D-Ala-NH2, Nal-Glu, Abarelix, Degarelix, and acetyl-D2Nal-D4CIPhe-D3Pal-Ser-Aph(Ac)-D-Aph(Ac)-Leu-Lys(lpr)-Pro-D-Ala-NH2.

Abstract: The present invention provides a heart homing peptide that contains the amino acid sequence GGGVFWQ (SEQ ID NO: 2); HGRVRPH (SEQ ID NO: 3); VVLVTSS (SEQ ID NO: 4); CLHRGNSC (SEQ ID NO: 9); or CRSWNKADNRSC (SEQ ID NO: 10) and further provides conjugates in which a heart homing peptide is linked to a moiety such as a therapeutic agent. The conjugates of the invention are useful for treating cardiovascular diseases such as atherosclerosis and restenosis.

Abstract: Compounds having the formula

Abstract: This invention encompasses the novel compounds of Formula I, which are useful in the treatment of caspase-3 mediated diseases.

Abstract: N-[1-oxo-2-alkyl-3-(N-hydroxyformamido)-propyl]-(carbonylamino-aryl or -heteroaryl)-azacyclo4-7alkanes or thiazacyclo4-7alkanes or imidazacyclo4-7alkanes have interesting properties, e.g., in the treatment or prevention of disorders amenable to treatment by peptidyl deformylase inhibitors such as treatment of bacterial infections.

Abstract: A method of treating hyperresorptive bone disorders through the direct inhibition of the Src protein tyrosine kinase involves administering a pharmaceutically effective amount of certain amide, sulfonamide, and urea compounds; whereas, these compounds may also be used for inhibiting the Src protein tyrosine kinase generally in humans for therapeutic purposes.

Abstract: The invention provides an amino acid usable for reducing and/or preventing the coloration caused by a combined use of saccharide and amino acid, and an amino acid usable as a stabilizer for a dry composition containing a pharmacologically active proteinaceous substance. The invention also provides an anti-coloring agent containing a hydrophobic amino acid as an essential ingredient suitable for preventing the coloration of a dry composition containing a saccharide, a method for preventing the coloration of a dry composition containing a saccharide using a hydrophobic amino acid, and a dry composition containing a pharmacologically active proteinaceous substance which further comprises a saccharide and a hydrophpbic amino acid as a stabilizer.

Abstract: This disclosure is for the nutrient, D-ribose, as well as other nutrient precursors of ATP and NAD when desired, to be administered with one or more anti-microbial agents for the purpose of enabling the anti-microbial agents to function better in combating infection than if the D-ribose were not given, plus enabling the nutrient D-ribose to improve the ability of the cloaking protein Sir2p to protect genes from attack further strengthening the immune system against infection.

Abstract: A glucoside containing isomaltol represented by formula (I): 1

Abstract: The present invention relates to methods of providing crystalline and crystal-like forms of daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention relates to methods of purifying daptomycin.

Abstract: The invention is directed to a methods of reducing the viability of a proliferating mammalian cells such as cancer cells. In one method cells deficient in p53 activity and in p53 suppressor activity of one or more p53-interacting regulatory proteins cell viability is reduced by increasing the level or activity of p53 in the cell. In another method viability of cells exhibiting p53 activity and p53 suppressor activity of one or more p53-interacting regulatory proteins is reduced by reducing the suppressor activity of the one or more p53-interacting regulatory proteins. Further, cell viability is reduced in cells deficient in p53 activity and exhibiting p53 suppressor activity of one or more p53-interacting regulatory proteins by a method that includes: (a) increasing the level or activity of p53 in the cell, and (b) reducing the suppressor activity of the one or more p53-interacting regulatory proteins.

Abstract: The invention relates to ribozymes modified to improve their stability, methods for producing such enzymes and the use of the modified enzymes in methods such as therapeutic treatment. In particular, a typical ribozyme according to the invention includes a modified ribozyme, wherein three or more pyrimidine nucleotides in said ribozyme are modified at the 2′-position, wherein said pyrimidine nucleotides are modified to 2′-amino pyrimidine nucleotides and said ribozyme exhibits improved stability to RNAse degradation and exhibits 85% or more catalytic activity of the unmodified ribozyme.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Phospholipase A2, group IIA (synovial). The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Phospholipase A2, group IIA (synovial). Methods of using these compounds for modulation of Phospholipase A2, group IIA (synovial) expression and for treatment of diseases associated with expression of Phospholipase A2, group IIA (synovial) are provided.

Abstract: Antisense oligonucleotides containing one or more degenerate and/or universal bases, and one or more modified backbone linkages, and use of these oligonucleotides for cleaving target RNA molecules.

Abstract: The present invention provides methods for modulating angiogenesis by administering anti-angiogenic FGF-19 polypeptides to a subject. Methods of modulating angiogenesis by administering an anti-angiogenic FGF-19 nucleic acid are also provided.

Abstract: This patent describes the invention of a series of novel therapeutic oligonucleotides targeted at inhibiting expression of genes coding for Phosphodiesterase 4. They are useful as analytical tools in the study of individual PDE isoforms and in the therapeutic treatment of depression, thrombosis, cystic fibrosis, gastric lesions, pulmonary hypertension, glaucoma, multiple sclerosis, atopic dermatitis, asthma and other allergic disorders as well as other illnesses in which an increase of cyclic AMP or a decrease in phosphodiesterase levels is useful.

Abstract: The present invention provides methods for identification of cancerous cells by detection of expression levels of TTK, as well as diagnostic, prognostic and therapeutic methods that take advantage of the differential expression of these genes in mammalian cancer. Such methods can be useful in determining the ability of a subject to respond to a particular therapy, e.g., as the basis of rational therapy. In addition, the invention provides assays for identifying pharmaceuticals that modulate activity of these genes in cancers in which these genes are involved, as well as methods of inhibiting tumor growth by inhibiting activity of TTK.

Abstract: The present invention relates to techniques of skin-targeted non-invasive gene delivery to elicit immune responses and uses thereof. The invention further relates to methods of non-invasive genetic immunization in an animal and/or methods of inducing a systemic immune or therapeutic response in an animal following topical application of vectors, products therefrom and uses for the methods and products therefrom. The methods can include contacting skin of the animal with a vector in an amount effective to induce the systemic immune or therapeutic response in the animal as well as such a method further including disposing the vector in and/or on the delivery device. The vector can be gram negative bacteria, preferably Salmonella and most preferably Salmonella typhimurium.

Abstract: The present invention provides compositions comprising a 3′-OH, 5′-OH, chemically unmodified, synthetic phosphodiester nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and a pharmaceutically acceptable carrier, wherein the compositions are useful to induce differentiation of cells or to stimulate differentiation or production of pluripotent cells. The present invention provides methods of using these compositions to induce differentiation of pluripotent cells, including bone marrow derived cells, and to treat disease associated with insufficient differentiation of cells in animals and humans, including but not limited to leukemia, lymphoma, non-malignant blood disorders such as hemoglobinopathies, sickle cell disease, myelodysplastic syndrome, pancytopenia, anemia, thrombocytopenia and leukopenia.

Abstract: Disclosed are synthetic oligonucleotides complementary to nucleic acids encoding epidermal growth factor and methods of their use.

Abstract: A method for controlling in vivo heat-inducible gene expression for provision of therapeutic polypeptide. The method includes the steps of: (a) providing a construct comprising a polynucleotide encoding a therapeutic polypeptide, wherein the polynucleotide is operatively linked to a heat-inducible promoter; (b) administering the construct to a warm-blooded vertebrate at a site at or near the tumor; and (c) applying heat to the site at or near the tumor to express the therapeutic polypeptide, whereby anti-tumor activity is observed.

Abstract: Methods for inhibiting the growth of tumor cells by combination treatment with a selenium-containing prodrug and an enzyme for which it is a substrate are described. The treatment also enhances the effect of anti-tumor agents.

Abstract: The invention relates to vectors produced in a donor host cell, which upon transfer into a receiver host cell maintain the desired expression of the nucleotide sequences that are located within the vector. The maintenance of the desired expression is achieved because the vector at least partly remains unmethylated within the receiver host cell. The donor host cell is different as compared to the receiver host cell and the receiver host cell being capable of methylating DNA. The invention also relates to methods for the production of such vectors and the use of the vectors in industry as well as in medicine.

Abstract: The present invention is directed to a method of prophylactically or therapeutically treating an animal for at least one ocular-related disorder, e.g., ocular neovascularization or age-related macular degeneration. The method comprises contacting an ocular cell with an expression vector comprising a nucleic acid sequence encoding an inhibitor of angiogenesis and the same or different nucleic acid sequence encoding a neurotrophic agent. The method also can comprise contacting an ocular cell with different expression vectors, each comprising a nucleic acid sequence encoding an inhibitor of angiogenesis and/or a nucleic acid sequence encoding a neurotrophic agent. In addition, the present invention provides a viral vector comprising a nucleic acid sequence encoding pigment epithelium-derived factor (PEDF) or a therapeutic fragment thereof.

Abstract: The present invention relates to immunotherapy methods for treating hyperproliferative disease or pathogen-induced diseases in humans. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in hyperproliferative cells. In another embodiment, an adenoviral expression construct comprising a self gene under the control of a promoter operable in eukaryotic cells is intradermally administered to said hyperproliferative cells. In another embodiment of the present invention, a pathogen-induced disease in which the pathogen gene expression is increased or altered, is treated by intradermally administered a pathogen gene under the control of a promoter operable in eukaryotic cells.

Abstract: The instant invention is a method of using certain analogs of glutamic acid and gamma-aminobutyric acid in combination with an anti-viral agent to treat shingles.

Abstract: A method for reducing elevated plasma LDL and/or triglyceride levels in an HIV-infected patient is disclosed. In this method, atazanavir (BMS-232632) can be used to treat HIV infection in patients exhibiting elevated plasma LDL-cholesterol and/or triglyceride levels, can be substituted for an offending HIV protease inhibitor used in such therapy, or can be used in combination with an HIV protease inhibitor metabolized by cytochrome P450 monooxygenase.

Abstract: An oral intake solution reduced in bitterness and thus easy to administer orally is produced by dissolving a water-soluble component giving a bitter taste, e.g., vitamin B group, into reduced water obtained, e.g., by electrolysis. The pH value of the solution is preferably adjusted to from 2 to 7.

Abstract: A stable, formulation comprising glucosamine and chondroitin compounds in a base which can be used for topical application to relieve joint pain and myofascial pain. A method of preparing the composition by adding the glucosamine and chondroitin after the rest of the components of the formulation have been mixed and heated is also disclosed.

Abstract: A method is provided for regulating carbohydrate and fat metabolism is an individual which method comprises replacing a proportion of the individual's daily carbohydrate intake with resistant starch and a proportion of the individual's saturated fat intake with unsaturated fat.

Abstract: The invention concerns a composition comprising at least a first constituent which is an oligosaccharide of formula (I) containing 3 to 5 oside units and having at least a D-galactose unit bound by an &agr;[1-6] bond with a sucrose unit. The invention is characterized in that in said sucrose unit R1, R2, R3, R4, independently of one another represent a hydrogen atom, an alkyl group containing 1 to 10 carbon atoms and optionally having at least an unsaturation, a sulphate function or else an ose and, at least a second constituent which is a molecule positively charged with a physiological pH and stimulating pinocytosis or a molecule stimulating membrane penetration.

Abstract: The present invention relates to methods of treating an individual with diabetes mellitus by administering to said individual an effective amount of copper chelators, hydrazine compounds, and/or substrate analogues. The invention also relates to methods of treating an individual with diabetes mellitus by lessening fructosamine odixase activity in said individual. Provided within is disclosure pertaining to treatment, pharmaceutical compositions, dosage ranges, and uses of fructosamine oxidase enzyme inhibitors to lessen fructosamine oxidase activity.

Abstract: Bis (fluoroaryl) borane derivative is produced by reacting tris (fluoroaryl) borane with a compound, such as water, ethanol, ammonia and the like, in a hydrocarbon solvent at a molar ratio raging from 1:0.9 to 1:1.1. It is more preferable that the reaction is carried out while the hydrocarbon solvent is distilled off. It is more preferable that hydrocarbon solvent is substantially an aliphatic hydrocarbon solvent. With this arrangement, it is possible to provide a method for producing and isolating the bis (fluoroaryl) borane derivative of a high purity, with ease and at a low cost.

Abstract: The present invention relates to (1R, cis)-4-(4-Amino-7H-pyrrolo[2,3-(d)]pyrimidine-7-yl)-2-cyclopentene-1-methanol derivatives for the treatment of viral infections.

Abstract: The invention provides a stabilized 1&agr;-hydroxyvitamin D (“SHVD”) which is particularly well suited for pharmaceutical formulations.

Abstract: Estrogen-Plus will be a single pill 2 cm long, 1 cm wide, and about 0.5 cm thick, containing 1.25 to 2.5 mg of Estrogen, 100 mcg Selenium, 15 mg Zinc, 120 mcg Chromium, 150 mg Calcium, 2 mg Copper, 100 mg Phosphorus, 150 mg Magnesium, 75 mcg Molybdenum, 150 mcg Iodine, 5,000 IU Beta Carotene, 60 mg Ascorbic Acid, 400 IU Vitamin D, 30 IU Vitamin E, 80 mcg Vitamin K, 1.5 mg Thiamin, 1.7 mg Riboflavin, 2 mg Vitamin B6, 6 mcg Vitamin B12, 400 mcg Folic Acid, 18 mg Iron, 1 mg Pantothenic Acid, 300 mcg Biotin, and inert fillers and binders necessary for manufacture.

Abstract: This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: 1

Abstract: According to one aspect of the invention, there is provided a pharmaceutical formulation for administration by inhalation comprising a compound of formula (I), 1

Abstract: A solvent comprising a combination of water and organic solvent(s) capable of dissolving a therapeutically effective amount of medicament(s) not readily soluble in aqueous solvents, said organic solvents including alcohol and glycol, and said medicaments including hydrocortisone.

Abstract: 17-Methyleneandrostan-3&agr;-ol analogs are useful as corticotropin releasing hormone (CRH) inhibitors, and especially as anti-depressants, when administered to the vomeronasal organ. An improved synthesis of 17-methylenandrost-4-en-3&agr;-ol is disclosed.